.jpg)
FDA Grants IND Approval to Triastek’s 3D Printed Oral Anticoagulant T20G
Triastek, a Chinese 3D printing pharmaceutical company, has announced that its proprietary 3D printed non-vitamin K antagonist oral anticoagulant (NOAC), T20G, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) as of February 27, 2025. This regulatory achievement follows an earlier IND approval from China’s National Medical Products Administration […]
Triastek, a Chinese 3D printing pharmaceutical company, has announced that its proprietary 3D printed non-vitamin K antagonist oral anticoagulant (NOAC), T20G, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) as of February 27, 2025. This regulatory achievement follows an earlier IND approval from China’s National Medical Products Administration […]
